Building A Biotech Hub with Intellia Therapeutics' John Leonard, M.D.
Jan 15, 2024
auto_awesome
Dr. John Leonard, longtime CEO at Intellia Therapeutics, discusses the foundational elements of building a biotech hub, the influence of the AIDS epidemic on his career, the importance of experience and knowledge in scientific research, and Intellia's long-term DNA editing strategy. He also provides updates on the company's clinical pipeline and future plans.
Building a successful biotech requires a diverse community with resources, intellectual property, and support.
Balancing short-term projects with faster returns and long-term goals is crucial for attracting and retaining investor interest in biotech companies.
Deep dives
Building a Successful Biotech
Dr. John Leonard, President and CEO of Intellia Therapeutics, discusses the importance of building a successful biotech and the need for a community of diverse resources and ecosystem. He emphasizes the role of experience, expertise, and collaboration in the biotech industry. Dr. Leonard shares his own journey from a background in R&D to becoming a business builder, highlighting the significance of having a molecular understanding of diseases and exploring new ways to intervene. He also discusses the role of technology, especially CRISPR, in driving innovation and the importance of balancing both short-term and long-term goals in building a biotech company.
Navigating the Challenges of Funding
Dr. Leonard acknowledges the challenges of funding in the biotech industry, especially for pre-commercial companies. He explains that fluctuations in economic conditions, such as rising interest rates and economic uncertainty, have led to increased risk aversion among investors. As a result, biotech companies need to be more thoughtful and strategic about capital preservation, efficient budget planning, and demonstrating a clear path to future value creation. Dr. Leonard also suggests that new biotech leaders should consider focusing on shorter-term projects with faster returns to attract and retain investor interest.
The Collaborative Nature of the Biotech Community
Dr. Leonard highlights the collaborative and community-driven nature of the biotech industry. He discusses the importance of sharing knowledge, insights, and methodologies with fellow scientists and entrepreneurs. While intellectual property and trade secrets are zealously protected, the biotech community thrives on sharing ways of thinking, problem-solving approaches, and collective progress. Dr. Leonard emphasizes that this collaborative mindset is conducive to innovation, as it allows for a broader exchange of ideas and the building of stronger scientific foundations.
Intellia's Clinical Progress and Future Outlook
Dr. Leonard provides an update on Intellia's clinical pipeline, highlighting ongoing and upcoming trials. He mentions that Intellia's phase three programs for TTR amyloidosis and hereditary angioedema are progressing well. In addition, the company is focusing on expanding its gene-editing technologies beyond the liver into other tissues, such as the brain, muscle, and eye. Dr. Leonard also mentions that Intellia has programs in ophthalmological diseases, immunology settings, and allogeneic ex vivo therapies, which are in the late stages of discovery. Overall, the company is in a strong position to advance innovative gene-editing solutions to benefit patients.
We spend a lot of time talking with our guests about building biotech companies. That’s true of this episode too, but today we’re taking a step further with John Leonard, M.D., longtime CEO at Intellia Therapeutics. In addition to how he’s built late-clinical stage Intellia, Dr. Leonard shares the foundational elements of a biotech community, particularly around rapidly-advancing technologies such as CRISPR, and what biotech ecosystems offer emerging biotechs in terms of resources, intellectual property, and support. Turns out that despite his proximity, Boston isn’t the prerequisite it used to be. This is an instructive conversation with an industry vet who’s happy to share the wealth of his knowledge.
Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.